Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 669
- Registration Number
- NCT02107703
- Locations
- 🇲🇽
OCA Hospital, Monterrey, Nuevo León, Mexico
🇺🇸Kaiser Permanente, Riverside, California, United States
🇺🇸University of California - San Diego, La Jolla, California, United States
A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT02106364
- Locations
- 🇺🇸
Diagnostic Rheumatology and Research, Indianapolis, Indiana, United States
🇺🇸Florida Medical Clinic PA, Zephyrhills, Florida, United States
🇺🇸Heartland Research Associates, Wichita, Kansas, United States
A Study of LY2951742 in Healthy Japanese and Caucasian Participants
- Conditions
- Migraine Disorders
- Interventions
- Drug: LY2951742Drug: Placebo
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT02104765
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cypress, California, United States
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 132
- Registration Number
- NCT02102490
- Locations
- 🇺🇸
Texas Oncology-Plano West, Plano, Texas, United States
🇺🇸Northwest Cancer Specialists PC, Vancouver, Washington, United States
🇺🇸Univ of California San Francisco, San Francisco, California, United States
A Study of Cephalexin in Healthy Participants
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT02100826
- Locations
- 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico
A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2018-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 270
- Registration Number
- NCT02091362
- Locations
- 🇺🇸
University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸Cedar-Crosse Research Center, Chicago, Illinois, United States
🇺🇸National Research Institute, Los Angeles, California, United States
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
- Conditions
- Advanced CancerGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaHepatocellular CancerRenal Cell CarcinomaNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 97
- Registration Number
- NCT02082210
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-small Cell Lung
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 142
- Registration Number
- NCT02079636
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Indiana Cancer Pavilion, Indianapolis, Indiana, United States
🇺🇸The West Clinic, Germantown, Tennessee, United States
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 192
- Registration Number
- NCT02072096
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States
🇺🇸Carolina Health Specialists, Myrtle Beach, South Carolina, United States
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Biological: RamucirumabDrug: FOLFOX4
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8
- Registration Number
- NCT02069041
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taoyuan City, Taiwan